Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer

Advances in Cancer Research

Volumn 127, Issue , 2015, Pages 123-158

  Martin, Sarah K ^a   Kyprianou, Natasha ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Androgen receptor; Castration resistant prostate cancer; Chemotherapy; Taxanes

Indexed keywords

ABC TRANSPORTER; ABIRATERONE; ABIRATERONE ACETATE; AFLIBERCEPT; ANDROGEN RECEPTOR; ANDROSTANOLONE; ANTINEOPLASTIC AGENT; ATRASENTAN; BETA TUBULIN; BEVACIZUMAB; CABAZITAXEL; CUSTIRSEN; CYCLIC AMP DEPENDENT PROTEIN KINASE; DASATINIB; DOCETAXEL; ENZALUTAMIDE; EPI 002; KINESIN; MICROTUBULE ASSOCIATED PROTEIN; MOLECULAR MOTOR; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; PROTEIN KINASE PIM 1; PROTEIN P53; STATHMIN; TAXANE DERIVATIVE; TESTOSTERONE; TRANSCRIPTION FACTOR ERG; TRANSCRIPTION FACTOR FKHR; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZIBOTENTAN; ANTIANDROGEN; TAXOID;

ADDICTION; ADVANCED CANCER; AMINO TERMINAL SEQUENCE; ANDROGEN SYNTHESIS; ANTIANDROGEN THERAPY; BINDING SITE; CANCER RESISTANCE; CANCER SURVIVAL; CARBOXY TERMINAL SEQUENCE; CASTRATION RESISTANT PROSTATE CANCER; CENTROSOME; CONFORMATIONAL TRANSITION; CROSS RESISTANCE; CYTOPLASM; DRUG INTERMITTENT THERAPY; EPITHELIAL MESENCHYMAL TRANSITION; GENE MUTATION; HUMAN; MALE; MICROTUBULE; NONHUMAN; OVERALL SURVIVAL; PROSTATE CANCER CELL LINE; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; CELL CYCLE CHECKPOINT; DRUG EFFECTS; DRUG RESISTANCE; G2 PHASE CELL CYCLE CHECKPOINT; GENETICS; METABOLISM; PREVENTION AND CONTROL; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TUMOR RECURRENCE;

ANDROGEN ANTAGONISTS; ANIMALS; CELL CYCLE CHECKPOINTS; DRUG RESISTANCE, NEOPLASM; G2 PHASE CELL CYCLE CHECKPOINTS; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; TAXOIDS;

EID: 84945436172     PISSN: 0065230X     EISSN: None     Source Type: Book Series    
DOI: 10.1016/bs.acr.2015.03.001     Document Type: Chapter

References (173)

1. Abdulla A., Kapoor A. Emerging novel therapies in the treatment of castrate-resistant prostate cancer. Canadian Urological Association Journal 2011, 5(2):120-133.
2. Acloque H., Adams M.S., Fishwick K., Bronner-Fraser M., Nieto M.A. Epithelial-mesenchymal transitions: The importance of changing cell state in development and disease. The Journal of Clinical Investigation 2009, 119(6):1438-1449.
3. Andersen R.J., Mawji N.R., Wang J., Wang G., Haile S., Myung J.-K., et al. Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor. Cancer Cell 2010, 17:535-546.
4. Antonarakis E.S., Eisenberger M.A. Phase III trials with docetaxel-based combinations for metastatic castration-resistant prostate cancer: Time to learn from past experiences. Journal of Clinical Oncology 2013, 31(14):1709-1712.
5. Antonarakis E.S., Lu C., Wang H., Luber B., Nakazawa M., Roeser J.C., et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. The New England Journal of Medicine 2014, 371(11):1028-1038.
6. Aoki S., Ohta K., Yamazaki T., Sugawara F., Sakaguchi K. Mammalian mitotic centromere associated kinesin (MCAK): A new molecular target of sulfoquinovosylacylglycerols novel antitumor and immunosuppressive agents. The FEBS Journal 2005, 272:2132-2140.
7. Araujo J.C., Trudel G.C., Saad F., Armstrong A.J., Yu E.Y., Bellmunt J., et al. Overall survival (OS) and safety of dasatinib/docetaxel versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC) 2013.
8. Attard G., Cooper C.S., de Bono J.S. Steroid hormone receptors in prostate cancer: A hard habit to break?. Cancer Cell 2009, 16:458-462.
9. Attard G., Greystroke A., Kaye S., De Bono J. Update on tubulin targeting agents. Pathologie Biologie 2006, 54:72-84.
10. Azarenko O., Smiyun G., Mah J., Wilson L., Jordan M.A. Antiproliferative mechanism of action of the novel taxane cabazitaxel as compared with the parent compound docetaxel in MCF7 breast cancer cells. Molecular Cancer Therapeutics 2014, 13(8):2092-2103.
11. Barrallo-Gimeno A., Nieto M.A. The Snail genes act as inducers of cell movement and survival: Implications in development and cancer. Development 2005, 132:3151-3161.
12. Beer T.M., Ryan C.W., Venner P.M., Petrylak D.P., Chatta G.S., Ruether J.D., et al. Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer: Results from ASCENT, a double-blinded, randomized comparison of high dose calcitriol plus docetaxel with placebo plus docetaxel. Cancer 2008, 112:326-330.
13. Bellmunt J., Albiol S., Albanell J. Intermittent chemotherapy in metastatic androgen-independent prostate cancer. BJU International 2007, 100:490-492.
14. Belmont L.D., Mitchison T.J. Identification of a protein that interacts with tubulin dimers and increases the catastrophe rate of microtubules. Cell 1996, 84:623-631.
15. Berthold D.R., Pond G.R., Soban F., de Wit R., Eisenberger M., Tannock I.F. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival in the TAX 327 study. Journal of Clinical Oncology 2008, 26:242-245.
16. Bianchini D., Lorente D., Rodriguez-Vida A., Omlin A.G., Pezaro C.J., Ferraldeschi R., et al. Antitumor activity of enzalutamide (MDV3100) in patients with metastatic castration resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone. European Journal of Cancer 2014, 50:78-84.
17. Black B.E., Paschal B.M. Intranuclear organization and function of the androgen receptor. Trends in Endocrinology and Metabolism 2004, 15:411-417.
18. Brasso K., Thomsen F.B., Schrader A.J., Schmid S.C., Lorente D., Retz M., et al. Enzalutamide antitumour activity against metastatic castration resistant prostate cancer previously treated with docetaxel and abiraterone: A multicentre analysis. European Urology. 2014, Epub ahead of print. doi:10.1016/j.euro.2014.07.028.
19. Brinkmann A.O., Blok L.J., de Ruiter P.E., Doesburg P., Steketee K., Berrevoets C.A., et al. Mechanisms of androgen receptor activation and function. The Journal of Steroid Biochemistry and Molecular Biology 1999, 69(1):307-313.
20. Brodsky A.S., Silver P.A. Nuclear transport HEATs up. Nature Cell Biology 1999, 1:E66-E67.
21. Bruckheimer E.M., Kyprianou N. Dihydrotestosterone enhances transforming growth factor beta induced apoptosis in hormone sensitive prostate cancer cells. Endocrinology 2001, 142:2419-2426.
22. Bruckheimer E.M., Kyprianou N. BCL-2 antagonizes the combined apoptotic effect of transforming growth factor-beta and dihydrotestosterone in prostate cancer cells. Prostate 2002, 53:133-142.
23. Bruno R., Sanderink G.J. Pharmacokinetics and metabolism of Taxotere (docetaxel). Cancer Surveys 1993, 17:305-313.
24. Chan S.C., Li Y., Dehm S.M. Androgen receptor splice variants activate AR target genes and support aberrant prostate cancer cell growth independent of the canonical AR nuclear localization signal. The Journal of Biological Chemistry 2012, 287(23):19736-19749.
25. Chandhok N.S., Pellman D. A little CIN may cost a lot: Revisiting aneuploidy and cancer. Current Opinion in Genetics & Development 2009, 19:74-81.
26. Chang W., Gruber D., Chari S., Kitazawa H., Hamazumi Y., Hisanaga S.-I., et al. Phosphorylation of MAP4 affects microtubule properties and cell cycle progression. Journal of Cell Science 2001, 114:2879-2887.
27. Chen C.D., Welsbie D.S., Tran C., Baek S.H., Chen R., Vessella R., et al. Molecular determinants of resistance to antiandrogen therapy. Nature Medicine 2004, 10(1):33-39.
28. Chi K., Hotte S.J.M., Yu E.Y., Tu D., Eigl B.J., Tannock I., et al. Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. Journal of Clinical Oncology 2010, 28(27):4247-4254.
29. Chien A.J., Moasser M.M. Cellular mechanisms of resistance to anthracyclines and taxanes in cancer: Intrinsic and acquired. Seminars in Oncology 2008, 35(S2):S1-S14.
30. Cisternino S., Bourasset F., Archimbaud Y. Nonlinear accumulation in the brain of the new taxoid TXD258 following saturation of P-glycoprotein at the blood-brain barrier in mice and rats. British Journal of Pharmacology 2003, 138:1367-1375.
31. Clark J., Merson S., Jhavar S., Flohr P., Edwards S., Foster C.S., et al. Diversity of TMPRSS2-ERG fusion transcripts in the human prostate. Oncogene 2007, 26:2667-2673.
32. Corbett A.H., Silver P.A. Nucleocytoplasmic transport of macromolecules. Microbiology and Molecular Biology Reviews 1997, 61:193-211.
33. Cutress M.L., Whitaker H.C., Mills I.G., Stewart M., Neal D.E. Structural basis for the nuclear import of the human androgen receptor. Journal of Cell Science 2008, 121:957-968.
34. Darshan M.S., Loftus M.S., Thadani-Mulero M., Levy B.P., Escuin D., Zhou X.K., et al. Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. Cancer Research 2011, 71(18):6019-6029.
35. Dayyani F., Gallick G.E., Logothetis C.J., Corn P.G. Novel therapies for metastatic castrate-resistant prostate cancer. Journal of the National Cancer Institute 2011, 103:1665-1675.
36. De Bono J.S., Logothetis C.J., Molina A., Fizazi K., North S., Chu L., et al. Abiraterone and increased survival in metastatic prostate cancer. The New England Journal of Medicine 2011, 364:1995-2005.
37. De Bono J.S., Oudard S., Ozguroglu M., Hansen S., Machiels J.P., Kocak I., et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. Lancet 2010, 376:1147-1154.
38. De S., Cipriano R., Jackson M.W., Stark G.R. Overexpression of kinesins mediates docetaxel resistance in breast cancer cells. Cancer Research 2009, 69:8035-8042.
39. Debes J.D., Tindall D.J. Mechanisms of androgen refractory prostate cancer. The New England Journal of Medicine 2004, 351:1488-1490.
40. Dehm S.M., Schmidt L.J., Heemers H.V., Vessella R.L., Tindall D.J. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Research 2008, 68:5469-5477.
41. Desai A., Verma S., Mitchison T.J., Walczak C.E. Kin I kinesins are microtubule-destabilizing enzymes. Cell 1999, 96:69-78.
42. Di Lorenzo G., Buonerba C., De Placido S., Sternberg C.N. Castration-resistant prostate cancer: Current and emerging treatment strategies. Drugs 2010, 70(8):983-1000.
43. Ding S., Zhao Z., Sun D., Wu F., Bi D., Lu J., et al. Eg5 inhibitor, a novel potent targeted therapy, induces cell apoptosis in renal cell carcinoma. Tumor Biology 2014, 35(8):7659-7668.
44. Duran G.E., Wang Y.C., Francisco E.B., Rose J.C., Martinez F.J., Coller J., et al. Mechanisms of resistance to cabazitaxel. Molecular Cancer Therapeutics 2014, 14(1):193-201. 10.1158/1535-7163.MCT-14-0155.
45. Feldman B.J., Feldman D. The development of androgen-independent prostate cancer. Nature Reviews. Cancer 2001, 1(1):34-45. 10.1038/35094009.
46. Feng J., Zheng S.L., Wennuan L., Isaacs W.B., Xu J. Androgen receptor signaling in prostate cancer: New twists for an old pathway. Steroids & Hormonal Science 2011, S2:1-7.
47. Fizazi K., Higano C.S., Nelson J.B., Gleave M., Miller K., Morris T., et al. Phase III randomized, placebo controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer. Journal of Clinical Oncology 2013, 31:1740-1747.
48. Fizazi K., Scher H.I., Molina A., Logothetis C.J., Chi K., Jones R.J., et al. Abiraterone acetate for treatment of metastatic castration resistant prostate cancer: Final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. The Lancet. Oncology 2012, 13(10):983-992.
49. Freedland S.J., Moul J.W. Prostate specific antigen recurrence after definitive therapy. The Journal of Urology 2007, 177(6):1985-1991.
50. Friedrich B., Grongberg H., Landstrom M., Gullberg M., Bergh A. Differentiation stage specific expression of oncoprotein 18 in human and rat prostatic adenocarcinoma. Prostate 1995, 27:102-109.
51. Galletti G., Matov A., Beltran H., Fontugne J., Mosquera J.M., Cheung C., et al. ERG induces taxane resistance in castration-resistant prostate cancer. Nature Communications 2014, 5:1-12.
52. Galsky M.D., Dritselis A., Kirkpatrick P., Oh W.K. Cabazitaxel. Nature Reviews. Drug Discovery 2010, 9:677-678.
53. Gan L., Chen S., Wang Y., Watahiki A., Bohrer L., Sun Z., et al. Inhibition of the androgen receptor as a novel mechanisms of taxol chemotherapy in prostate cancer. Cancer Research 2009, 69(21):8386-8394.
54. Ganguly A., Yang H., Cabral F. Overexpression of mitotic centromere associated kinesin stimulates microtubule detachment and confers resistance to paclitaxel. Molecular Cancer Therapeutics 2011, 10:929-937.
55. Gelmann E.P. Molecular biology of the androgen receptor. Journal of Clinical Oncology 2002, 13:3001-3015.
56. Giannakakou P., Gussio R., Nogales E., Downing K.H., Zharevitz D., Bollbuck B., et al. A common pharmacophore for epothilone and taxanes: Molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. PNAS 2000, 97:2904-2909.
57. Giannakakou P., Sackett D., Kang Y.-K., Zhan Z., Buters J.T.M., Fojo T., et al. Paclitaxel-resistant human ovarian cancer cells have mutant Beta-tubulins that exhibit impaired paclitaxel-driven polymerization. The Journal of Biological Chemistry 1997, 272:17118-17125.
58. Gleave M., Miyake H. Use of antisense oligonucleotides targeting the cytoprotective gene, clusterin, to enhance androgen- and chemo-sensitivity in prostate cancer. World Journal of Urology 2005, 23:38-46.
59. Gleave M., Miyake H., Zellweger T., Chi K., July L., Nelson C., et al. Use of antisense oligonucleotides targeting the antiapoptotic gene, clusterin/testosterone-repressed prostate message 2, to enhance androgen sensitivity and chemosensitivity in prostate cancer. Urology 2001, 58(2A):39-49.
60. Goeckeler W.F., Edwards B., Volkert W.A., Holmes R.A., Simon J., Wilson D. Skeletal localization of samarium-153 chelates: Potential therapeutic bone agents. Journal of Nuclear Medicine 1987, 28:495-504.
61. Goncalves A., Braguer D., Kamath K., Martello L., Briand C., Horwitz S.B., et al. Resistance to Taxol in lung cancer cells associated with increased microtubules dynamics. PNAS 2001, 98(20):11737-11742.
62. Gorlich D. Nuclear protein import. Current Opinion in Cell Biology 1997, 9:412-419.
63. Haldar S., Basu A., Croce C.M. Bcl2 is the guardian of the microtubule integrity. Cancer Research 1997, 57:229-233.
64. Haraguchi M., Okubo T., Miyashita Y., Miyamoto Y., Hayashi M., Crotti T.N., et al. Snail regulates cell-matrix adhesion by regulation of the expression of integrins and basement membrane proteins. The Journal of Biological Chemistry 2008, 283:23514-23523.
65. Heemers H.V., Tidall D.J. Androgen receptor (AR) coregulators: A diversity of functions converging on and regulating the AR transcriptional complex. Endocrine Reviews 2007, 28(7):778-808.
66. Heinlein C.A., Chang C. Androgen receptor (AR) coregulators: An overview. Endocrine Reviews 2002, 23:175-200.
67. Hermans K.G., Van Marion R., Van Dekken H., Jenster G., Van Weerden W.M., Trapman J. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late stage androgen receptor negative prostate cancer. Cancer Research 2006, 66:10658-10663.
68. Hoffman-Censits J., Kelly W.K. Enzalutamide: A novel antiandrogen for patients with castrate-resistant prostate cancer. Clinical Cancer Research 2013, 19(6):1335-1339.
69. Hotte S.J.M., Saad F. Current management of castrate resistant prostate cancer. Current Oncology 2010, 17:S72-S79.
70. Hu R., Denmeade S.R., Luo J. Molecular processes leading to aberrant androgen receptor signaling and castration resistance in prostate cancer. Expert Review of Endocrinology and Metabolism 2010, 5(5):753-764.
71. Huggins C., Hodges C.V. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatase in metastatic carcinoma of the prostate. Cancer Research 1941, 1:293-297.
72. Huizing M.T., Misser V.H.S., Pieters R.C., ten Bokkel Huinink W.W., Veenhof C.H.N., Vermorken J.B., et al. Taxanes: A new class of antitumor agents. Cancer Investigation 1995, 13(4):381-404.
73. Huzil J.T., Chen K., Kurgan L., Tuszynski J.A. The roles of beta-tubulin mutations and isotype expression in acquired drug resistance. Cancer Informatics 2007, 3:159-181.
74. Kahn B., Collazo J., Kyprianou N. Androgen receptor as a driver of therapeutic resistance in advanced prostate cancer. International Journal of Biological Sciences 2014, 10(6):588-595.
75. Kalluri R. EMT: When epithelial cells decide to become mesenchymal-like cells. The Journal of Clinical Investigation 2009, 119(6):1417-1419.
76. Kalluri R., Weinberg R.A. The basics of epithelial-mesenchymal transition. The Journal of Clinical Investigation 2009, 119(6):1420-1428.
77. Kelly W.K., Halabi S., Carducci M.A., George D.J., Mahoney J.F., Stadler W.M., et al. Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. Journal of Clinical Oncology 2012, 30(13):1534-1540.
78. Kraus L.A., Samuel S.K., Schmid S.M., Dykes D.J., Waud W.R., Bissery M.C. The mechanism of action of docetaxel (Taxotere) in xenograft models is not limited to bcl-2 phosphorylation. Investigational New Drugs 2003, 21:259-268.
79. Kwon M., Godinho S.A., Chandhok N.S., Ganem N.J., Azioune A., Thery M., et al. Mechanisms to suppress multipolar divisions in cancer cells with extra centrosomes. Genes & Development 2008, 22(16):2189-2203.
80. Lin A.M., Ryan C.J., Small E.J. Intermittent chemotherapy for metastatic hormone refractory prostate cancer. Critical Reviews in Oncology/Hematology 2007, 61(3):243-254.
81. Liu X., Gong H., Huang K. Oncogenic role of kinesin proteins and targeting kinesin therapy. Cancer Science 2013, 104(6):651-656.
82. Liu P., Li S., Gan I., Kao T.P., Huang H. A transcription-independent function of FOXO1 in inhibition of androgen-independent activation of the androgen receptor in prostate cancer cells. Cancer Research 2008, 68:10290-10299.
83. Lonergan P.E., Tindall D.J. Androgen receptor signaling in prostate cancer development and progression. Journal of Carcinogenesis 2011, 10(20):1-12.
84. Loriot Y., Bianchini D., Ileana E., Sandhu S., Patrikidou A., Pezaro C.J., et al. Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). Annals of Oncology 2013, 00:1-6.
85. Luadena R.F. Multiple forms of tubulin: Different gene products and covalent modifications. International Review of Cytology 1998, 178:207-275.
86. Madan R.A., Pal S.K., Sartor O., Dahut W.L. Overcoming chemotherapy resistance in prostate cancer. Clinical Cancer Research 2011, 17(12):3892-3902.
87. Mahon K.L., Henshall S.M., Sutherland R.L., Horvath L.G. Pathways of chemotherapy resistance in castration resistant prostate cancer. Endocrine-Related Cancer 2011, 18:R103-R123.
88. Makarovskiy A.N., Siryaporn E., Hixson D.C., Akerley W. Survival of docetaxel resistant prostate cancer cells in vitro depends on phenotype alterations and continuity of drug exposure. Cellular and Molecular Life Sciences 2002, 59:1198-1211.
89. Marklund U., Larsson N., Gradin H., Brattsand G., Gullberg M. Oncoprotein 18 is a phosphorylation-responsive regulator of microtubule dynamics. The EMBO Journal 1996, 15:5290-5298.
90. Martin S.K., Banuelos C.A., Sadar M.D., Kyprianou N. N-terminal targeting of androgen receptor variant enhances response of castration resistant prostate cancer to taxane chemotherapy. Molecular Oncology 2015, 9(3):628-639.
91. Martin S.K., Pu H., Horbinski C., Cao Z., Strup S.E., Kyprianou N. Targeting mitotic kinesin with next-generation taxane Cabazitaxel to overcome castration resistant prostate cancer 2015, Submitted.
92. Matuszak E.A., Kyprianou N. Androgen regulation of epithelial-mesenchymal transition in prostate tumorigenesis. Expert Review of Endocrinology and Metabolism 2011, 6(3):469-482.
93. Mistry S.J., Atweh G.F. Therapeutic interactions between stathmin inhibition and chemotherapeutic agents in prostate cancer. Molecular Cancer Therapeutics 2006, 5(12):3248-3257.
94. Moreno-Bueno G., Portillo F., Cano A. Transcriptional regulation of cell polarity in EMT and cancer. Oncogene 2008, 27:6958-6969.
95. Murphy M., Hinman A., Levine A.J. Wild-type p53 negatively regulates the expression of a microtubule-associated protein. Genes & Development 1996, 10(23):2971-2980.
96. Nadal R., Zhang Z., Rahman H., Schweizer M.T., Denmeade S.R., Paller C.J., et al. Clinical activity of enzalutamide in docetaxel-naive and docetaxel-pretreated patients with metastatic castration-resistant prostate cancer. Prostate 2014, 74:1560-1568.
97. Nakabayashi M., Sartor O., Jacobus S., Regan M.M., McKearn D., Ross R.W., et al. Response to docetaxel/carboplatin-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer. BJU International 2008, 101(3):308-312.
98. Nakouzi N.A., Le Moulec S., Albiges L., Wang C., Beuzeboc P., Gross-Goupil M., et al. Cabazitaxel remains active in patients progressing after docetaxel followed by novel androgen receptor pathway targeted therapies. European Urology 2014, Epub ahead of print.
99. Nazareth L.V., Weigel N.L. Activation of the human androgen receptor through a protein kinase A signaling pathway. The Journal of Biological Chemistry 1996, 271:19900-19907.
100. Nigg E.A. Nucleocytoplasmic transport: Signals, mechanisms, and regulation. Nature 1997, 386:779-787.
101. Ning Y.M., Gulley J.L., Arlen P.M., Woo S., Steinberg S.M., Wright J.J., et al. Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration resistant prostate cancer. Journal of Clinical Oncology 2010, 28(12):2070-2076.
102. Noonan K.L., North S., Bitting R.L., Armstrong A.J., Ellard S.L., Chi K.N. Clinical activity of abiraterone acetate in patients with metastatic castration resistant prostate cancer progressing after enzalutamide. Annals of Oncology 2013, 24:1802-1807.
103. Ogawa T., Nitta R., Okada Y., Hirokawa N. A common mechanism for microtubule destabilizers-M type kinesins stabilize curling of the protofilament using the class-specific neck and loops. Cell 2004, 116:591-602.
104. Ogden A., Rida P.C., Aneja R. Let's huddle to prevent a muddle: Centrosome declustering as an attractive anticancer strategy. Cell Death and Differentiation 2012, 19(8):1255-1267.
105. Ogden A., Rida P.C., Aneja R. Heading off with the herd: How cancer cells might maneuver supernumerary centrosomes for directional migration. Cancer Metastasis Reviews 2013, 32(1-2):269-287.
106. Oliver C.L., Miranda M.B., Shangary S., Land S., Wang S., Johnson D.E. (-)-Gossypol acts directly on the mitochondria to overcome Bcl-2 and Bcl-X(L) mediated apoptosis resistance. Molecular Cancer Therapeutics 2005, 4:23-31.
107. Orr G.A., Verdier-Pinard P., McDaid H., Band Horwitz S. Mechanisms of taxol resistance related to microtubules. Oncogene 2003, 22:7280-7295.
108. Peindao H., Olmeda D., Cano A. Snail, Zeb, bHLH factors in tumor progression: An alliance against the epithelial phenotype?. Nature Reviews. Cancer 2007, 7:415-428.
109. Petrylak D.P., Fizazi K., Sternberg C.N., Budnik N., De Wit R., Wiechno P.J., et al. A phase III study to evaluate the efficacy and safety of docetaxel and prednisone with or without lenalidomide in patients with castrate resistant prostate cancer: The MAINSAIL trial 2012.
110. Petrylak D.P., Tangen C.M., Hussain M.H., Lara P.N., Jones J.A., Taplin M.E., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. The New England Journal of Medicine 2004, 351:1513-1520.
111. Pezaro C.J., Omlin A.G., Altavilla A., Lorente D., Ferraldeschi R., Bianchini D., et al. Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents. European Urology 2014, 66(3):459-465.
112. Picard D., Yamamoto K.R. Two signals mediate hormone-dependent nuclear localization of the glucocorticoid receptor. The EMBO Journal 1987, 6:3333-3340.
113. Ploussard G., Terry S., Maille P., Allory Y., Sirab N., Kheuang L., et al. Class III beta-tubulin expression predicts prostate tumor aggressiveness and patient response to docetaxel based chemotherapy. Cancer Research 2010, 70(22):9253-9264.
114. Poruchynsky M.S., Giannakakou P., Ward Y., Bulinski J.C., Telford W.G., Robey R.W., et al. Accompanying protein alterations in malignant cells with a microtubule-polymerizing drug-resistance phenotype and a primary resistance mechanisms. Biochemical Pharmacology 2001, 62:1469-1480.
115. Poukka H., Karvonen U., Yoshikawa N., Tanaka H., Palvimo J.J., Janne O.A. The RING finger protein SNURF modulates nuclear trafficking of the androgen receptor. Journal of Cell Science 2000, 113:2991-3001.
116. Quinn D.I., Tangen C.M., Hussain M., Lara P., Goldkorn A., Garzotto M., et al. SWOG SO421: Phase III study of docetaxel and atrasentan versus docetaxel and placebo for men with advanced castrate-resistant prostate cancer 2012.
117. Rath O., Kozielski F. Kinesins and cancer. Nature Reviews. Cancer 2012, 12:527-539.
118. Regan M.M., O'Donnell E.K., Kelly W.K., Halabi S., Berry W., Urakami S., et al. Efficacy of carboplatin-taxane combinations in the management of castration-resistant prostate cancer: A pooled analysis of seven prospective clinical trials. Annals of Oncology 2010, 21(2):312.
119. Rickert K.W. Discovery and biochemical characterization of selective ATP competitive inhibitors of the human mitotic kinesin KSP. Archives of Biochemistry and Biophysics 2008, 469:220-231.
120. Roy A.K., Lavrosky Y., Song C.S. Regulations of androgen action. Vitamins and Hormones 1999, 55:309-352.
121. Sadar M.D. Small molecule inhibitors targeting the "Achilles' Heel" of androgen receptor activity. Cancer Research 2011, 71(4):1208-1213.
122. Sanhaji M., Friel C.T., Kreis N.-N., Kramer A., Martin C., Howard J., et al. Functional and spatial regulation of mitotic centromere associated kinesin by cyclin-dependent kinase 1. Molecular and Cellular Biology 2010, 30(11):2594-2607.
123. Sanhaji M., Friel C.T., Worderman L., Louwen F., Yuan J. Mitotic centromere-associated kinesin (MCAK): A potential cancer drug target. Oncotarget 2011, 2(12):935-947.
124. c (cabazitaxel): Full prescribing information 2014, http://www.jevtana.com.
125. Sartor A.O. Progression of metastatic castrate-resistant prostate cancer: Impact of therapeutic intervention in the post-docetaxel space. Journal of Hematology & Oncology 2011, 4:18.
126. Sartor O., Reid R.H., Hoskin P., Quick D.P., Ell P.J., Coleman R.E., et al. Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology 2004, 63:940-945.
127. Savory J.G.A., Hsu B., Laquian I.R., Giffin W., Reich T., Hache R.J.G., et al. Discrimination between NL1- and NL2-mediated nuclear localization of the glucocorticoid receptor. Molecular and Cellular Biology 1999, 19:1025-1037.
128. Schaufele F., Carbonell X., Guerbadot M., Borngraeber S., Chapman M.S., Ma A.A.K., et al. The structural basis of androgen receptor activation: Intramolecular and intermolecular amino-carboxy interactions. Proceedings of the National Academy of Sciences of the United States of America 2005, 102:9802-9807.
129. Scher H.I., Beer T.M., Higano C.S., Anand A., Taplin M.E., Efstanthiou E., et al. Antitumor activity of MDV3100 in castration resistant prostate cancer: A phase 1-2 study. Lancet 2010, 375:1437-1446.
130. Scher H.I., Fizazi K., Saad F., Taplin M.E., Sternberg C.N., Miller K., et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. The New England Journal of Medicine 2012, 367:1187-1197.
131. Schmidt L.J., Tindall D.J. Steroid 5 alpha reductase inhibitors targeting BPH and prostate cancer. The Journal of Steroid Biochemistry and Molecular Biology 2011, 125:32-38.
132. Schmizzi G.V., Currie J.D., Rogers S.L. Expression levels of a kinesin-13 microtubule depolymerase modulates the effectiveness of anti-microtubule agents. PloS One 2010, 5:e11381.
133. Schutz F.A., Buzaid A.C., Sartor O. Taxanes in the management of metastatic castration-resistant prostate cancer: Efficacy and management of toxicity. Critical Reviews in Oncology/Hematology 2014, 91(3):248-256.
134. Serafini A.N., Houston S.J., Resche I., Quick D.P., Grund F.M., Ell P.J., et al. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: A double-blind placebo-controlled clinical trial. Journal of Clinical Oncology 1998, 16:1574-1581.
135. Shen H.C., Balk S.P. Development of androgen receptor antagonists with promising activity in castration-resistant prostate cancer. Cancer Cell 2009, 15(6):461-463.
136. Siegsmund M.J., Kreukler C., Steidler A. Multidrug resistance in androgen independent growing rat prostate carcinoma cells is mediated by P-glycoprotein. Urological Research 1997, 25:35-41.
137. Sircar K., Huang H., Limei H., Liu Y., Dhillon J., Cogdell D., et al. Mitosis phase enrichment with identification of mitotic centromere-associated kinesin as a therapeutic target in castration resistant prostate cancer. PloS One 2012, 7(2):1-8.
138. Small E.J., Demkow T., Gerritsen W.R., Rolland F., Hoskin P., Smith D.C., et al. A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel versus docetaxel plus prednisone in symptomatic, castration resistant prostate cancer (CRPC) 2009.
139. Sprenger C.C.T., Plymate S.R. The link between androgen receptor splice variants and castration-resistant prostate cancer. Hormones and Cancer 2014, 5:207-217.
140. Sternberg C.N., Petrylak D.P., Sartor O., Witjes J.A., Demkow T., Ferrero J.-M., et al. Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: The SPARC trial. Journal of Clinical Oncology 2009, 27(32):5431-5438.
141. Sullivan G.F., Yang J.M., Vassil A., Yang J., Bash-Babula J., Hait W.N. Regulation of expression of the multidrug resistance protein MRP1 by p53 in human prostate cancer cells. The Journal of Clinical Investigation 2000, 105:1261-1267.
142. Sun S., Sprenger C.C.T., Vessella R.L., Haugk K., Soriano K., Mostaghel E.A., et al. Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. The Journal of Clinical Investigation 2010, 120(8):2715-2730.
143. Takeda M., Mizokami A., Mamiya K., Li Y.Q., Zhang J., Keller E.T., et al. The establishment of two paclitaxel-resistant prostate cancer cell lines and the mechanisms of paclitaxel resistance with two cell lines. Prostate 2007, 67:955-967.
144. Tan M.H., De S., Bebek G., Orloff M.S., Wesolowski R., Downs-Kelly E., et al. Specific kinesin expression profiles associated with taxane resistance in basal-like breast cancer. Breast Cancer Research and Treatment 2012, 131(3):849-858.
145. Tannock I., de Wit R., Berry W.R., Horti J., Pluzanska A., Chi K.N., et al. Docetaxel plus prednisone or mitoxantrone and prednisone for advanced prostate cancer. The New England Journal of Medicine 2004, 351:1502-1512.
146. Tannock I., Fizazi K., Ivanov S., Thellenberg Karlsson C., Flechon A., Skoneczna I.A., et al. Aflibercept versus placebo in combination with docetaxel/prednisone for first line treatment of men with metastatic castration-resistant prostate cancer (mCRPC): Results from the multinational phase III trial (VENICE) 2013.
147. Terry S., Ploussard G., Allory Y., Nicolaiew N., Boissiere-Michot F., Maille P., et al. Increased expression of class III beta-tubulin in castration resistant human prostate cancer. British Journal of Cancer 2009, 101(6):951-956.
148. Thadani-Mulero M., Portella L., Sun S., Sung M., Matov A., Vessella R.L., et al. Androgen receptor splice variants determine taxane sensitivity in prostate cancer. Cancer Research 2014, 74(8):2270-2282.
149. Theyer G., Schirmbock M., Thalhammer T. Role of the MDR-1 encoded multiple drug resistance phenotype in prostate cancer cell lines. The Journal of Urology 1993, 150:1544-1547.
150. Thiery J.P., Acloque H., Huang R.Y., Nieto M.A. Epithelial-mesenchymal transitions in development and disease. Cell 2009, 139(5):871-890.
151. Tomlins S.A., Laxman B., Varambally S., Cao X., Yu J., Helgeson B.E., et al. Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia 2008, 10(2):177-188.
152. Tomlins S.A., Rhodes D.R., Perner S., Dhanasekaran S.M., Mehra R., Sun X.-W., et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005, 310:644-648.
153. Tran C., Ouk S., Clegg N.J., Chen Y., Watson P.A., Arora V., et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009, 324:787-790.
154. Van Royen M.E., Cunha S.M., Brink M.C., Mattern K.A., Nigg A.L., Dubbink H.J., et al. Compartmentalization of androgen receptor protein-protein interactions in living cells. The Journal of Cell Biology 2007, 177:63-72.
155. van Royen M.E., van Cappellen W.A., de Vos C., Houtsmuller A.B., Trapman J. Stepwise androgen receptor dimerization. Journal of Cell Science 2012, 125:1970-1979.
156. Vishnu P., Tan W.W. Update on options for treatment of metastatic castration-resistant prostate cancer. OncoTargets and Therapy 2010, 3:39-51.
157. Vrignaud P., Semiond D., Lejeune P., Bouchard H., Calvet L., Combeau C., et al. Preclinical antitumor activity of cabazitaxel, a semisynthetic taxane active in taxane-resistant tumors. Clinical Cancer Research 2013, 19(11):2973-2983.
158. Walcak J.R., Carducci M.A. Prostate cancer: A practical approach to current management of recurrent disease. Mayo Clinic Proceedings 2007, 82:243-249.
159. Watson P.A., Chen Y.F., Balbas M.D., Wongvipat J., Socci N.D., Viale A., et al. Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full length androgen receptor. Proceedings of the National Academy of Sciences of the United States of America 2010, 107:16759-16765.
160. Williams K., Ghosh R., Gridhar P.V., Gu G., Case T., Belcher S.M., et al. Inhibition of stathmin1 accelerates the metastatic process. Cancer Research 2012, 72(20):5407-5417.
161. Wilson J.D. The role of 5 alpha-reduction in steroid hormone physiology. Reproduction, Fertility, and Development 2001, 13:673-678.
162. Wiltshire C., Singh B.L., Stockley J., Fleming J., Doyle B., Barnetson R., et al. Docetaxel-resistant prostate cancer cells remain sensitive to S-trityl-L-cysteine-mediated Eg5 inhibition. Molecular Cancer Therapeutics 2010, 9(6):1730-1739.
163. Wissing M.D., De Morree E.S., Dezentje V.O., Buijs J.T., De Krijger R.R., Smit V.T.H.B.M., et al. Nuclear Eg5 (kinesin spindle protein) expression predicts docetaxel response and prostate cancer aggressiveness. Oncotarget 2014, 5(17):7357-7367.
164. Xie Y., Xu K., Linn D.E., Yang X., Guo Z., Shimelis H., et al. The 44-kDa Pim-1 kinase phosphorylates BCRP/ABCG2 and thereby promotes its multimerization and drug resistant activity in human prostate cancer cells. The Journal of Biological Chemistry 2008, 283(6):3349-3356.
165. Yang C.P., Liu L., Ikui A.E., Horwitz S.B. The interaction between mitotic checkpoint proteins, CENP-E and BubR1, is diminished in epothilone-B resistant A549 cells. Cell Cycle 2010, 9:1207-1213.
166. Yang J., Weinberg R. Epithelial-mesenchymal transition: At the crossroads of development and tumor metastasis. Developmental Cell 2008, 14(6):818-829.
167. Yilmaz M., Christofori G. EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Reviews 2009, 28:15-33.
168. Zalcberg J., Hu X.F., Slater A., Parisot J., El-Osta S., Kantharidis P., et al. MRP1 not MDR1 gene expression is the predominant mechanism of acquired multidrug resistance in two prostate carcinoma cell lines. Prostate Cancer and Prostatic Diseases 2000, 3:66-75.
169. Zellweger T., Chi K., Miyake H., Adomat H., Kiyama S., Skov K., et al. Enhanced radiation sensitivity in prostate cancer by inhibition of the cell survival protein clusterin. Clinical Cancer Research 2002, 8:3276-3284.
170. Zhang X., Lan W., Ems-McClung S.C., Stukenberg P.T., Walczak C.E. Aurora B phosphorylates multiple sites on mitotic centromere-associated kinesin to spatially and temporally regulate its function. Molecular Biology of the Cell 2007, 18:3264-3276.
171. Zhang C.C., Yang J.M., White E., Murphy M., Levine A.J., Hait W.N. The role of MAP4 expression in the sensitivity to paclitaxel and resistance to vinca alkaloids in p53 mutant cells. Oncogene 1998, 16:1617-1624.
172. Zhou Z.X., Sar M., Simental J.A., Lane M.V., Wilson E.M. A ligand dependent bipartite nuclear targeting signal in the human androgen receptor. Requirement for the DNA-binding domain and modulation by the NH2 terminal and carboxyl-terminal sequences. The Journal of Biological Chemistry 1994, 269(18):13115-13123.
173. Zhu M.-L., Horbinski C., Garzotto M., Qian D.Z., Beer T.M., Kyprianou N. Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. Cancer Research 2010, 70(20):7992-8002.